Lily Secures External Advisor for COVID-19 Drug Plant Problem

Indianapolis based pharmaceutical company Eli Lily and Co. (LLY) has announced that it has procured services of an external advisor to review its COVID-19 drug plant problem.

This comes after inspectors from Food and Drug Administration (FDA) found Lily’s drug for COVID-19 violating quality control standards resulting to the company halting its vaccine development trials.

According to the report by FDA inspectors, the drug was missing proper laboratory controls to maintain regulatory standards during drug manufacturing.

Among other errors FDA also discovered Lily had deleted and given false information in some documents so as to ensure employees were abiding by standards set by the FDA.

Last week the company said it had not received any warning letter from FDA after the inspection had been conducted however, several days later Lily confirmed having received an Official Action Indicated (OAI) notice concerning the drug from FDA.

The drug in question is similar to the Regeneron treatment U.S President Donald Trump received while he was admitted in the hospital after testing positive for the deadly virus.

Leave a comment

Your email address will not be published. Required fields are marked *